Avelumab Plus Axitinib for Translocation Renal Cell Carcinoma: A Case Series and Literature Review

Overview

Journal IJU Case Rep

Date 2024 Mar 5

PMID 38440705

Authors

Kenta Takahashi

Renpei Kato

Daiki Ikarashi

Tomohiko Matsuura

Shigekatsu Maekawa

Mitsugu Kanehira

Ryo Takata

Jun Sugimura

Takaya Abe

Wataru Obara

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment.

Case Presentation: The first case was of a 72-year-old woman who underwent robot-assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 90-week follow-up. The second case was of a 41-year-old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para-aortic lymph node. After treatment with avelumab-axitinib, continued progression-free survival was confirmed at the 43-week follow-up.

Conclusion: The outcomes of these cases indicate that avelumab-axitinib therapy has a long-term antitumor effect in some patients with tRCC.

References

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Menegon S, Columbano A, Giordano S . The Dual Roles of NRF2 in Cancer. Trends Mol Med. 2016; 22(7):578-593. DOI: 10.1016/j.molmed.2016.05.002. View

Powles T, Plimack E, Soulieres D, Waddell T, Stus V, Gafanov R . Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020; 21(12):1563-1573. DOI: 10.1016/S1470-2045(20)30436-8. View

Malouf G, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A . Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010; 21(9):1834-1838. DOI: 10.1093/annonc/mdq029. View

Paksoy N, Erdem S, Karaca M, Ak N, Pehlivan M, Yirgin I . Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report. J Oncol Pharm Pract. 2021; 28(1):215-221. DOI: 10.1177/10781552211020802. View

Motzer R, Rini B, Mcdermott D, Frontera O, Hammers H, Carducci M . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019; 20(10):1370-1385. PMC: 7497870. DOI: 10.1016/S1470-2045(19)30413-9. View

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

Boileve A, Carlo M, Barthelemy P, Oudard S, Borchiellini D, Voss M . Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. J Immunother Cancer. 2018; 6(1):159. PMC: 6307255. DOI: 10.1186/s40425-018-0482-z. View

Motzer R, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K . Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(1):71-90. PMC: 10191161. DOI: 10.6004/jnccn.2022.0001. View

10.

Tomita Y, Motzer R, Choueiri T, Rini B, Miyake H, Uemura H . Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. ESMO Open. 2022; 7(2):100450. PMC: 9058903. DOI: 10.1016/j.esmoop.2022.100450. View

11.

Choueiri T, Lim Z, Hirsch M, Tamboli P, Jonasch E, Mcdermott D . Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010; 116(22):5219-25. PMC: 4667556. DOI: 10.1002/cncr.25512. View

12.

Lee C, Voss M, Carlo M, Chen Y, Zucker M, Knezevic A . Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022; 40(21):2333-2341. PMC: 9287282. DOI: 10.1200/JCO.21.01944. View

13.

Bakouny Z, Sadagopan A, Ravi P, Metaferia N, Li J, Abuhammad S . Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022; 38(1):110190. PMC: 9127595. DOI: 10.1016/j.celrep.2021.110190. View

14.

Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R . Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020; 84:101966. DOI: 10.1016/j.ctrv.2020.101966. View